Although PLC levels may serve as a biomarker of the magnitude of myocardial ischemia and reperfusion injury, our study suggests that targeting PLC formation, specifically, does not hold a therapeutic promise in the context of myocardial infarction. The gene discussed is HSPG2; the disease is myocardial ischemia.